摘要
头颈部鳞癌(head neck squamous cell carcinoma,SCCHN)外科治疗和放化疗技术虽不断发展,但疗效并未获得满意的改善。作为一种新的抗肿瘤治疗方式,表皮生长因子受体(epidermal growthfactor receptor,EGFR)靶向治疗在结直肠癌和肺癌中已经得到了成功的应用。由于EGFR在SCCHN中同样有着高表达率,故靶向治疗是否也能用于SCCHN患者成为了目前的研究热点。虽然多项EGFR临床试验均显示出良好的前景,但EGFR抑制剂目前仍主要应用于二、三线辅助治疗中。本文主要讨论各种EGFR靶向药物治疗SCCHN的研究进展及未来的研究方向。
Despite continuing progresses of surgery, chemotherapy and radiotherapy of treating head neck squamous cell carcinoma （SCCHN） in decades, significant survival improvements have not been observed. As a novel antitumor treatment, EGFR targeted therapy had been used successfully in the treatment of colorectal and lung cancer. Overexpression of EGFR is also found in SCCHN, while the efficacy and safety of targeted therapy remain in controversies. Although several clinical trials have demonstrated an inspiring prospect, its application still remains second-line. This review discussed the advances, problems and future directions of this novel therapy.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2012年第12期934-941,共8页
China Oncology
基金
国家自然基金(No:81272934
81001204)
关键词
头颈部鳞癌
表皮生长因子受体
靶向治疗
耐药机制
疗效预测因子
Squamous cell carcinoma of the head and neck
Epidermal growth factor receptor
Moleculartargeted therapy
Resistance mechanism
Predictor of response
